CyberKnife Treatment for Shoulder Metastasis from Lung Cancer

September 15, 2025 Lisa Park Tech
News Context
At a glance
  • Respiratory Syncytial Virus ⁢(RSV) is a common respiratory virus that usually causes mild, cold-like symptoms.
  • RSV spreads through close contact with infected individuals,much like the common cold.
  • The newly approved vaccine, Arexvy (GSK) and Abrysvo (Pfizer), uses a recombinant subunit vaccine technology.
Original source: cureus.com

Okay,I’m⁣ ready to transform the provided `

` content into a fully-formed,SEO-optimized,and accessible HTML5 `

`. As the `

` only contains a ``). ‍ I will focus on explaining the science in accessible terms, the impact on public health,‍ and what individuals should do.

Here’s ‍the HTML5 `

`:

RSV Vaccine Approved for older Adults: A Breakthrough in Respiratory Health

Table of Contents

What ⁢is RSV‍ and Why the new vaccine Matters

Respiratory Syncytial Virus ⁢(RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. Though, for older adults, RSV can lead to severe illness, including pneumonia and hospitalization. Untill recently, there was no vaccine to protect against RSV, leaving a significant gap ‍in preventative care for this vulnerable population. ⁢ In May 2023, the⁢ Food and Drug Administration (FDA) approved the first RSV vaccine for adults 60 years and older, ⁢marking a major public health achievement.

Understanding RSV: How it Works and why Older Adults are at Risk

RSV spreads through close contact with infected individuals,much like the common cold. It enters⁤ the body⁤ through the eyes, nose, or mouth. While ⁢most people recover within a⁢ week or two, older adults are more susceptible to severe complications due to age-related decline in immune function and the presence of underlying⁣ health conditions. This⁣ decline, known as immunosenescence, makes it harder for the body ⁢to fight off infections effectively.

The newly approved vaccine, Arexvy (GSK) and Abrysvo (Pfizer), uses a recombinant subunit vaccine technology. This means it doesn’t contain a live virus. Instead, it uses a specific protein⁣ from the⁤ RSV ⁤virus to trigger an immune response, preparing⁤ the body to fight off the virus if exposed. Clinical trials have demonstrated a high degree of efficacy⁢ in preventing severe RSV-related illness.

Vaccine Manufacturer efficacy (Severe RSV Disease)
Arexvy GSK 82.6%
Abrysvo Pfizer 94.1%
Efficacy data based on clinical trial results. Source: ⁢ FDA Press Release

The Public Health Impact: Reducing Hospitalizations and Improving Quality of Life

RSV is a significant burden on the healthcare system. According to the Centers for Disease Control‍ and Prevention (CDC), RSV leads to approximately 60,000-160,000 hospitalizations and 6,000-10,000 deaths among older adults each year in ⁣the United States. Widespread vaccination could dramatically reduce these numbers, freeing up hospital beds and resources.

Beyond hospitalization rates, the vaccine⁤ promises to improve the overall quality of life⁤ for older adults. Avoiding severe RSV illness means fewer missed social events, less disruption to daily routines, and a greater sense of well-being. ‍ This is particularly important for⁢ individuals ‍with chronic health conditions who are ⁣at‍ higher risk of ⁢complications.